CobiCure Therapeutics

CobiCure Therapeutics is a non-profit biotechnology company and venture philanthropy organization dedicated to accelerating the development of treatments for rare, life-threatening diseases. Launched by the foundation Cure Rare Disease, the company operates as a drug development engine designed to bridge the gap between academic discovery and clinical application. CobiCure focuses on customized therapeutic approaches, including CRISPR-based gene editing and antisense oligonucleotides, to address specific genetic mutations in pediatric populations. By leveraging a collaborative network of researchers, clinicians, and manufacturing partners, the organization aims to create a scalable and sustainable model for personalized medicine. Their lead program, CRD-TMH-001, represents a pioneering effort in using CRISPR technology for Duchenne muscular dystrophy.